ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton +11 more
wiley +1 more source
Adjunctive Use of Locally Delivered Statins in Periodontal Therapy and Pre-Implant Bone Regeneration: A Systematic Review and Meta-Analysis. [PDF]
Yoshida K +4 more
europepmc +1 more source
The association between cardiovascular medication use and survival in patients with advanced pancreatic adenocarcinoma. [PDF]
Mavros MN +5 more
europepmc +1 more source
Trends and inequalities in statin use for the primary and secondary prevention of cardiovascular disease between 2009 and 2021 in England: a series of cross-sectional and cohort studies. [PDF]
Muzambi R +6 more
europepmc +1 more source
Correction: Protective effect of statins in patients with sepsis-associated encephalopathy: a retrospective cohort study. [PDF]
Zhou T, Li L, Yi J, Gong X, Huang F.
europepmc +1 more source
Appropriateness and Outcome of a Statin Deprescription Intervention in Hospitalized Frail Older Adults: A Retrospective Study. [PDF]
Castiglia G +5 more
europepmc +1 more source
Potential of oral combination lipid‑lowering therapy beyond statins: a simulation‑based perspective from the SANTORINI study. [PDF]
Santos RD.
europepmc +1 more source

